Recent advances in the rational design and optimization of antibacterial agents

Jesse A. Jones, Kristopher G. Virga, Giuseppe Gumina, Kirk Hevener

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies. The focus of this review is on small-molecule compounds that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties. Agents are discussed that affect known antibacterial targets, such as the bacterial ribosome, nucleic acid binding proteins, and proteins involved in cell-wall biosynthesis; as well as some affecting novel bacterial targets which do not have currently marketed agents. The discussion of the agents focuses on the rational design strategies employed and the synthetic medicinal chemistry and structure-based design techniques utilized by the scientists involved in the discoveries, including such methods as ligand- and structure-based strategies, structure-activity relationship (SAR) expansion strategies, and novel synthetic organic chemistry methods. As such, the discussion is limited to small-molecule therapeutics that have confirmed macromolecular targets and encompasses only a fraction of all antibacterial agents recently approved or in late-stage clinical trials. The antibacterial agents selected have been recently approved for use on the U.S. or European markets or have shown promising results in phase 2 or phase 3 U.S. clinical trials.

Original languageEnglish (US)
Pages (from-to)1694-1715
Number of pages22
JournalMedChemComm
Volume7
Issue number9
DOIs
StatePublished - Jan 1 2016

Fingerprint

Anti-Bacterial Agents
Organic Chemistry
Phase III Clinical Trials
Molecules
Pharmacokinetics
Pharmaceutical Chemistry
Drug Design
Biosynthesis
Structure-Activity Relationship
Ribosomes
Cell Wall
Nucleic Acids
Carrier Proteins
Clinical Trials
Ligands
Pharmaceutical Preparations
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cite this

Recent advances in the rational design and optimization of antibacterial agents. / Jones, Jesse A.; Virga, Kristopher G.; Gumina, Giuseppe; Hevener, Kirk.

In: MedChemComm, Vol. 7, No. 9, 01.01.2016, p. 1694-1715.

Research output: Contribution to journalReview article

Jones, Jesse A. ; Virga, Kristopher G. ; Gumina, Giuseppe ; Hevener, Kirk. / Recent advances in the rational design and optimization of antibacterial agents. In: MedChemComm. 2016 ; Vol. 7, No. 9. pp. 1694-1715.
@article{4d9cea8ad2504c6b9741651c9fef8efe,
title = "Recent advances in the rational design and optimization of antibacterial agents",
abstract = "This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies. The focus of this review is on small-molecule compounds that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties. Agents are discussed that affect known antibacterial targets, such as the bacterial ribosome, nucleic acid binding proteins, and proteins involved in cell-wall biosynthesis; as well as some affecting novel bacterial targets which do not have currently marketed agents. The discussion of the agents focuses on the rational design strategies employed and the synthetic medicinal chemistry and structure-based design techniques utilized by the scientists involved in the discoveries, including such methods as ligand- and structure-based strategies, structure-activity relationship (SAR) expansion strategies, and novel synthetic organic chemistry methods. As such, the discussion is limited to small-molecule therapeutics that have confirmed macromolecular targets and encompasses only a fraction of all antibacterial agents recently approved or in late-stage clinical trials. The antibacterial agents selected have been recently approved for use on the U.S. or European markets or have shown promising results in phase 2 or phase 3 U.S. clinical trials.",
author = "Jones, {Jesse A.} and Virga, {Kristopher G.} and Giuseppe Gumina and Kirk Hevener",
year = "2016",
month = "1",
day = "1",
doi = "10.1039/c6md00232c",
language = "English (US)",
volume = "7",
pages = "1694--1715",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "9",

}

TY - JOUR

T1 - Recent advances in the rational design and optimization of antibacterial agents

AU - Jones, Jesse A.

AU - Virga, Kristopher G.

AU - Gumina, Giuseppe

AU - Hevener, Kirk

PY - 2016/1/1

Y1 - 2016/1/1

N2 - This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies. The focus of this review is on small-molecule compounds that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties. Agents are discussed that affect known antibacterial targets, such as the bacterial ribosome, nucleic acid binding proteins, and proteins involved in cell-wall biosynthesis; as well as some affecting novel bacterial targets which do not have currently marketed agents. The discussion of the agents focuses on the rational design strategies employed and the synthetic medicinal chemistry and structure-based design techniques utilized by the scientists involved in the discoveries, including such methods as ligand- and structure-based strategies, structure-activity relationship (SAR) expansion strategies, and novel synthetic organic chemistry methods. As such, the discussion is limited to small-molecule therapeutics that have confirmed macromolecular targets and encompasses only a fraction of all antibacterial agents recently approved or in late-stage clinical trials. The antibacterial agents selected have been recently approved for use on the U.S. or European markets or have shown promising results in phase 2 or phase 3 U.S. clinical trials.

AB - This review discusses next-generation antibacterial agents developed using rational, or targeted, drug design strategies. The focus of this review is on small-molecule compounds that have been designed to bypass developing bacterial resistance, improve the antibacterial spectrum of activity, and/or to optimize other properties, including physicochemical and pharmacokinetic properties. Agents are discussed that affect known antibacterial targets, such as the bacterial ribosome, nucleic acid binding proteins, and proteins involved in cell-wall biosynthesis; as well as some affecting novel bacterial targets which do not have currently marketed agents. The discussion of the agents focuses on the rational design strategies employed and the synthetic medicinal chemistry and structure-based design techniques utilized by the scientists involved in the discoveries, including such methods as ligand- and structure-based strategies, structure-activity relationship (SAR) expansion strategies, and novel synthetic organic chemistry methods. As such, the discussion is limited to small-molecule therapeutics that have confirmed macromolecular targets and encompasses only a fraction of all antibacterial agents recently approved or in late-stage clinical trials. The antibacterial agents selected have been recently approved for use on the U.S. or European markets or have shown promising results in phase 2 or phase 3 U.S. clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84988421417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988421417&partnerID=8YFLogxK

U2 - 10.1039/c6md00232c

DO - 10.1039/c6md00232c

M3 - Review article

VL - 7

SP - 1694

EP - 1715

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 9

ER -